Cart
sales@molnova.com
Sacituzumab
CAS No. 1796566-95-4
Sacituzumab( —— )
Catalog No. M34762 CAS No. 1796566-95-4
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 487 | In Stock |
|
| 10MG | 779 | In Stock |
|
| 25MG | 1188 | In Stock |
|
| 50MG | 1572 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSacituzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan).
-
DescriptionSacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1796566-95-4
-
Formula WeightApproximately 144 KDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. A Bardia, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156.?
molnova catalog
related products
-
P-XSC
P-XSC has anticancer activity, inhibits proliferation of colonic epithelial cells in patients with adenomatous polyps, and may be used in the study of breast cancer.
-
TP0586532
TP0586532 is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.
-
D-Fructose-6-phospha...
D-Fructose-6-phosphate (sodium salt hydrate) is a sugar intermediate in the glycolytic pathway produced by the isomerization of glucose 6-phosphate by glucose phosphate isomerase, and is used in cancer research.
